<DOC>
	<DOC>NCT01436617</DOC>
	<brief_summary>The main objective of this study is to validate the utility of IgE anti-cetuximab in the treatment strategy to identify patients at risk for a severe allergic reaction to cetuximab (grade 3 or 4 of the classification of NCI) and thus reduce the incidence of severe reactions.</brief_summary>
	<brief_title>Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab</brief_title>
	<detailed_description />
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Patient informed consent, Patient aged over 18 years Patients with a WHO performance status â‰¤ 2, Colon cancer or upper aerodigestive tract cytologically or histologically proven Patients with an indication to the theoretical use of cetuximab for colon neoplasia or upper aerodigestive tract, Haematological and biochemical compatible with combination therapy with cetuximab. Patients previously treated with cetuximab, A person deprived of liberty or under supervision.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>cancer</keyword>
	<keyword>colon</keyword>
	<keyword>Head and neck</keyword>
	<keyword>cetuximab</keyword>
	<keyword>anti-cetuximab dosage</keyword>
</DOC>